Access Vascular said today that it won a group purchasing agreement for a breakthrough technology with Premier for the HydroPICC peripherally inserted central catheter.
Bedford, Mass.-based Access Vascular’s HydroPICC is indicated for reduced thrombus accumulation. The catheter body is composed of biocompatible biomaterial, instead of the standard polyurethane as the material for the body.
The company said it has demonstrated a 97% reduction in thrombus accumulation, compared to traditional polyurethane PICCs.
After the FDA cleared the HydroPICC in February 2018, Access Vascular raised a total of $5 million, with a $2 million funding round in May and an additional $3 million round in August of last year.
Access said future applications aside from the HydroPICC include midlines, dialysis catheters, ports, and other devices.
“We are thrilled to be recognized by Premier as a breakthrough technology and are excited about the opportunity to introduce HydroPICC to Premier’s members,” Access founder & CEO James Biggins said in prepared remarks. “This contract will accelerate our commercialization by allowing us to get HydroPICC into the hands of a wider range of customers.”
